Skip to main content
All lobbying filings

RIVENDELL GROUP LLP

Lobbying for GENENTECH · Biotechnology company

 Filing 1st Quarter - Termination
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $30,000.00 income · posted Apr 24, 2026

Official filing document

 Lobbying activity 2
Health Issues

Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues relating to privacy and securing the data of and personal information of consumers General education on policies effecting development of pharmaceuticals, FDA approval and reimbursement.

Medicare/Medicaid

Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease;

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem